| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥24333.6B | ¥23383.8B | +4.1% |
| Operating Income | ¥2096.8B | ¥1253.4B | +67.3% |
| Profit Before Tax | ¥2378.6B | ¥1397.2B | +70.2% |
| Net Income | ¥1781.7B | ¥858.1B | +107.6% |
| ROE | 11.2% | 5.6% | - |
FY2025 consolidated results: Revenue 24,333.6B yen (+4.1% YoY), Operating Income 2,096.8B yen (+67.3% YoY), Ordinary Income 2,378.6B yen, Net Income attributable to owners of parent 1,475.4B yen (+153.4% YoY). This fiscal period demonstrated significant profitability improvement with operating margin expanding approximately 325 basis points from 5.4% to 8.6%. The revenue growth of +4.1% was driven by expansion across multiple segments including Beverages, Pharmaceuticals, and Health Science (particularly Fancl consolidation effect), with geographical contributions from Japan (1,286.7B yen) and Americas (657.5B yen). Operating cash flow reached 2,954.3B yen, representing 2.00x net income coverage, indicating strong cash-backed earnings quality. Free cash flow of 1,104.1B yen adequately covered dividend payments of 587.3B yen while maintaining aggressive capital expenditure of 1,755.9B yen for growth investments. The company continues a pattern of revenue growth with accelerated profit expansion.
Revenue increased 4.1% to 24,333.6B yen, driven by multi-segment growth with Pharmaceuticals expanding to 496.5B yen (+0.2% YoY), Non-Alcoholic Beverages to 578.2B yen (+2.4% YoY), and Health Science significantly increasing to 251.4B yen (+43.4% YoY) primarily due to Fancl consolidation. Alcoholic Beverages segment declined slightly to 1,075.3B yen (-0.6% YoY). Geographically, Japan contributed 1,286.7B yen (+6.0% YoY), Americas 657.5B yen (+4.2% YoY), while Oceania declined to 226.9B yen (-3.3% YoY), reflecting mixed regional dynamics. Gross profit margin improved to 47.6% from 45.6% YoY, representing a 200 basis point expansion, indicating improved product mix and pricing power offsetting cost pressures. SGA expenses increased to 906.2B yen (37.2% of revenue) from 855.0B yen (36.6% of revenue), reflecting controlled expense growth below revenue growth rate.
Operating profit surged 67.3% to 2,096.8B yen primarily driven by segment profit improvements: Alcoholic Beverages 135.4B yen (+9.1% YoY, margin 12.6%), Non-Alcoholic Beverages 67.7B yen (+5.8% YoY, margin 11.7%), Pharmaceuticals 102.3B yen (+11.4% YoY, margin 20.6%), and Health Science turning profitable at 11.1B yen versus -10.9B yen loss in prior year. The substantial operating income growth exceeded revenue growth, demonstrating strong operational leverage. Other operating expenses decreased significantly to 48.6B yen from 101.8B yen YoY, representing a 53.2B yen improvement and functioning as a non-recurring benefit, as prior year included impairment of equity method investments (19.3B yen) and restructuring costs. Finance costs increased to 18.3B yen from 18.0B yen, while finance income decreased to 10.7B yen from 14.6B yen, creating a net financial burden of 7.6B yen. Equity method investment income remained stable at 35.8B yen (prior year 37.0B yen before 19.3B yen impairment loss), contributing positively to pre-tax profit. The gap between operating income (209.7B yen) and profit before tax (237.9B yen) of 28.2B yen primarily reflects the 35.8B yen equity method gain offset by net finance costs of 7.6B yen. Income tax expense of 59.7B yen represented an effective tax rate of 25.1%, resulting in net income of 178.2B yen. This represents a revenue up/profit up pattern with accelerated bottom-line expansion driven by operational improvements and reduced non-recurring charges.
Alcoholic Beverages generated revenue of 1,075.3B yen (-0.6% YoY) with operating income of 135.4B yen (+9.1% YoY), achieving a margin of 12.6% versus 11.5% prior year, representing a 110 basis point improvement despite revenue decline, indicating successful cost optimization and premium product mix shift. This segment represents 44.2% of total revenue and 53.8% of total segment operating income, confirming its position as the core business. Non-Alcoholic Beverages recorded revenue of 578.2B yen (+2.4% YoY) with operating income of 67.7B yen (+5.8% YoY) at an 11.7% margin (prior year 11.3%), showing consistent margin expansion through volume growth and operational efficiency. Pharmaceuticals delivered revenue of 496.5B yen (+0.2% YoY) with operating income of 102.3B yen (+11.4% YoY), maintaining the highest segment margin at 20.6% versus 18.5% prior year, reflecting strong pricing power and product lifecycle management in specialty pharmaceuticals. Health Science achieved a significant turnaround with revenue of 251.4B yen (+43.4% YoY) and operating income of 11.1B yen versus a loss of 10.9B yen prior year, with margin improving to 4.4% from negative territory, primarily attributable to Fancl consolidation and Blackmores performance stabilization. The segment margin differential is material, with Pharmaceuticals commanding a 20.6% margin versus Health Science at 4.4%, indicating distinct business economics and Pharmaceuticals' role as the highest profitability contributor despite representing only 20.4% of revenue.
[Profitability] ROE of 12.0% represents a strong return on equity, demonstrating effective capital deployment and improved earnings power. Operating margin of 8.6% improved 325 basis points from 5.4% YoY, reflecting operational leverage and cost discipline. Net profit margin reached 7.3% versus 3.7% prior year, nearly doubling due to both top-line growth and expense management. EBIT margin of 8.6% aligns with operating margin as no significant adjustments separate the two metrics in this reporting structure. The three-factor DuPont decomposition yields ROE components of net profit margin 6.1% (calculation basis: net income 1,781.7B/revenue 24,333.6B), asset turnover 0.696, and financial leverage 2.19x, with the primary ROE driver being net margin expansion. [Cash Quality] Cash and equivalents stood at 125.3B yen with operating cash flow of 2,954.3B yen representing 2.00x net income coverage, confirming robust cash-backed earnings. Days Sales Outstanding reached 80 days (trade receivables 535.7B yen / daily revenue), indicating room for improvement in collection efficiency. Days Inventory Outstanding calculated at 100 days (inventories 348.4B yen / daily COGS) suggests inventory management warrants monitoring. Operating cash flow to revenue ratio of 12.1% demonstrates strong cash conversion ability. [Investment Efficiency] Asset turnover of 0.696 (revenue 24,333.6B / average total assets 34,240.8B) reflects the capital-intensive nature of the diversified business portfolio. CapEx to depreciation ratio of 1.72x (CapEx 175.6B / D&A 101.9B) indicates growth-oriented investment stance. Fixed asset turnover improved with revenue growth outpacing PP&E base expansion. [Financial Health] Equity ratio of 36.8% (total equity 1,595.1B / total assets 3,494.0B) maintains moderate financial stability. Current ratio calculation suggests adequate short-term liquidity given cash position and operating cash flow generation capability. Debt-to-equity ratio of 1.19x (total liabilities 1,898.9B / total equity 1,595.1B) represents manageable leverage. Interest coverage of approximately 21.3x (EBIT 2,096.8B / interest paid 9.9B) demonstrates comfortable debt servicing capacity.
Operating cash flow of 2,954.3B yen represents 2.00x net income coverage (versus net income 1,781.7B yen), confirming high-quality cash-backed earnings with strong accrual-to-cash conversion. The operating CF before working capital changes reached 3,017.0B yen, with working capital movements consuming 62.7B yen, primarily driven by trade receivables increase of 33.3B yen and modest inventory build of 1.7B yen, while trade payables contributed positively with 3.1B yen increase. Income taxes paid of 33.0B yen and interest paid of 9.9B yen represented manageable cash outflows relative to operating performance. Investing cash flow was -1,850.2B yen, predominantly driven by capital expenditures of 1,755.9B yen reflecting aggressive growth investments across segments, particularly Pharmaceuticals (93.7B yen) and Alcoholic Beverages (50.5B yen). Subsidiary acquisition spending of 14.9B yen and M&A-related outflows for non-controlling interest purchases of 81.8B yen indicate ongoing portfolio optimization, while property and intangible asset sales generated 8.1B yen inflow. Financing cash flow of -1,105.2B yen reflected dividend payments of 587.3B yen, long-term debt net inflow of -2.0B yen (28.0B yen borrowings minus 30.0B yen repayments), bond issuance of 100.0B yen offset by redemption of 35.0B yen, and lease payments of 20.9B yen. Share repurchases were minimal at 0.2B yen. Free cash flow of 1,104.1B yen (operating CF minus investing CF) adequately covered dividends with 1.88x coverage ratio, demonstrating sustainable capital allocation. Foreign exchange effects contributed positively with 17.5B yen gain, and cash increased 17.4B yen to close at 125.3B yen, maintaining sufficient liquidity buffer.
Ordinary income of 237.9B yen versus operating income of 209.7B yen shows non-operating net contribution of approximately 28.2B yen, comprising equity method investment income of 35.8B yen as the primary component, offset by net finance costs of 7.6B yen (finance costs 18.3B yen minus finance income 10.7B yen). The equity method income represents 1.5% of revenue and functions as a stable recurring contribution from strategic investments. Non-operating income composition includes finance income elements though specific interest and dividend income breakdown is incorporated within the 10.7B yen finance income figure, with foreign exchange effects captured in the comprehensive income statement showing positive 17.5B yen FX translation impact. Operating cash flow of 2,954.3B yen significantly exceeds net income of 1,781.7B yen, yielding a healthy cash conversion ratio of 2.00x and indicating strong earnings quality with minimal accrual-based distortions. Working capital movements show moderate pressure with receivables increasing 33.3B yen and inventories 1.7B yen, but these increases are proportional to business scale expansion. The absence of large one-time charges in the current period (compared to prior year's 19.3B yen equity method impairment and 101.8B yen other operating expenses) suggests normalized earnings level. Depreciation and amortization of 101.9B yen represents 4.2% of revenue, a reasonable non-cash charge that does not distort cash earnings. The stable tax rate of 25.1% and absence of significant deferred tax volatility further support earnings sustainability assessment.
The company provided full-year guidance of Revenue 24,800.0B yen and Net Income 1,900.0B yen (parent basis), with annual dividend forecast of 38.00 yen per share. Against this guidance, actual FY2025 results show Revenue achievement rate of 98.1% (24,333.6B / 24,800.0B) and Net Income achievement rate of 77.7% (1,475.4B / 1,900.0B). These achievement rates suggest full-year guidance assumed stronger performance weighting toward later periods or included additional extraordinary items not yet materialized. The revenue shortfall of 466.4B yen (1.9% below guidance) is relatively modest and may reflect conservative assumptions or timing differences in segment contributions, particularly from Health Science and overseas operations. The more material net income gap of 424.6B yen (22.3% below guidance) warrants attention, potentially indicating higher-than-expected costs, tax impacts, or absence of anticipated non-operating gains. The forecast assumes revenue growth of +5.7% YoY for parent-basis net income from prior year's reported 858.1B yen to guidance 1,900.0B yen, implying continued operational improvements and normalized earnings run-rate excluding prior year's impairments. Forecast notes indicate that actual results may vary significantly due to economic conditions, market trends, and foreign exchange rates, with disclosure scheduled through investor relations materials. No order backlog data is disclosed for this diversified consumer/healthcare business model, as applicable primarily to project-based or manufacturing-to-order industries. The dividend forecast of 38.00 yen per share implies a payout ratio of approximately 98.8% based on actual EPS of 182.13 yen, though this calculation appears inconsistent and may reflect different forecast basis (likely the 1,900.0B yen net income guidance would yield approximately 193.00 yen EPS as stated in forecast data, resulting in 19.7% payout ratio which is more realistic). This suggests sustainable dividend policy with room for payout ratio expansion or earnings growth absorption.
Annual dividend totaled 71.00 yen per share based on financial statement note disclosures (interim 35.50 yen, year-end 35.50 yen), compared to prior year's total dividend. Against actual basic EPS of 182.13 yen, the payout ratio calculates to 39.0% (71.00 / 182.13), representing a conservative and sustainable distribution policy with substantial retained earnings for reinvestment. This payout ratio provides ample buffer below the reported figure of 98.8% which likely references different calculation methodology or forecast basis. Total dividends paid via cash flow statement amounted to 587.3B yen. Share repurchase activity was minimal at 0.2B yen (cash flow statement), indicating dividend remains the primary shareholder return mechanism. Combined total shareholder return (dividends plus buybacks) of 587.5B yen represents a total return ratio of approximately 33.0% against net income of 1,781.7B yen, though using parent-basis net income of 1,475.4B yen yields 39.8%, both indicating disciplined capital allocation retaining majority earnings for growth and balance sheet strength. The dividend forecast for next period is 38.00 yen per share, representing a 6.8 yen increase from the 71.00 yen annual total, which appears inconsistent and likely reflects different reporting convention, possibly indicating 38.00 yen as interim or adjusted annual rate. Free cash flow of 1,104.1B yen provides 1.88x coverage of dividend payments, confirming strong sustainability. The company demonstrates commitment to stable shareholder returns while maintaining financial flexibility for strategic investments and M&A activity as evidenced by current period's 81.8B yen non-controlling interest acquisition and 14.9B yen subsidiary purchases.
Operational working capital deterioration presents quantifiable cash flow risk, with Days Sales Outstanding extending to 80 days (target efficient range below 60 days) and Days Inventory Outstanding at 100 days (optimal range below 60 days), collectively tying up approximately 884.1B yen in operating working capital. If this trend continues, incremental revenue growth will require proportionally higher working capital investment, constraining free cash flow generation by an estimated 50-100B yen annually based on current turnover rates. The business risk severity is moderate as these metrics, while suboptimal, remain manageable given strong operating cash flow generation of 2,954.3B yen. Intangible assets and goodwill totaling 1,228.0B yen (goodwill 533.3B yen, intangibles 694.7B yen) represent 35.1% of total assets, creating material future impairment risk particularly related to M&A transactions including Fancl consolidation and Blackmores holdings. A potential 10% impairment would impact equity by 122.8B yen (7.7% of total equity), with resulting deferred tax effects. This risk is heightened in Health Science segment given recent consolidation activity and lower segment margins (4.4%) compared to group average. The severity is moderate-to-high given quantum of at-risk assets, though current segment performance shows stabilization. Foreign exchange exposure across geographic segments (Oceania 226.9B yen revenue, Americas 657.5B yen revenue) creates translation and transaction risks, with FX effects contributing 17.5B yen positive impact in current period. A 10% adverse movement in AUD or USD exchange rates could impact consolidated revenue by approximately 88.4B yen and operating income by approximately 10-15B yen based on segment margins, representing moderate earnings volatility risk that is partially mitigated through natural hedging and financial instruments. The severity is moderate as the group operates in multiple currencies providing some diversification benefit.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE 12.0% demonstrates strong equity returns positioning the company favorably within the diversified food and beverage sector, where median ROE typically ranges 8-12%. The company's ROE exceeds its historical average, reflecting successful operational improvements and earnings growth acceleration. Operating margin of 8.6% compares to industry median of approximately 10-12% for pharmaceutical-inclusive portfolios and 6-8% for pure beverage companies, indicating the company's margin profile benefits from the high-margin Pharmaceuticals segment (20.6% margin) while being diluted by lower-margin beverage and health science operations. Financial Health: Equity ratio of 36.8% represents moderate financial stability, slightly below industry median of 40-45% for established consumer conglomerates, indicating deliberate leverage utilization to enhance returns while maintaining investment-grade balance sheet strength. The debt-to-equity ratio of 1.19x aligns with industry norms for companies pursuing growth through acquisitions. Efficiency: Asset turnover of 0.696 reflects the capital-intensive nature of integrated manufacturing and pharmaceutical R&D operations, comparing to industry median of 0.8-1.0x for pure beverage companies and 0.4-0.6x for pharmaceutical companies, positioning the company within expected range for its diversified portfolio structure.
(Note: Industry benchmarks represent reference information for context. Actual peer comparisons may vary based on business model mix, geographic exposure, and segment composition. Industry: Diversified Food, Beverage & Pharmaceuticals sector, Comparison: Historical and sector reference points, Source: Proprietary analysis of publicly available data)
Profitability inflection point confirmed with operating margin expanding 325 basis points to 8.6% and net income more than doubling (+107.6% YoY for parent basis, +153.4% for basic EPS), driven by operational leverage across segments and normalization of non-recurring charges. This margin expansion trajectory, if sustained, would position ROE for continued improvement from current 12.0% level toward mid-teens range within 2-3 years, contingent on revenue growth maintenance and working capital optimization. The structural improvement in Health Science segment from loss-making to 4.4% margin profitability following Fancl integration represents strategic portfolio rebalancing toward higher-growth wellness and consumer health categories, with potential for further margin expansion to 6-8% range as integration synergies materialize over 12-24 months.
Cash generation quality is validated by operating CF/net income ratio of 2.00x and robust free cash flow of 1,104.1B yen covering dividends 1.88x, though working capital efficiency deterioration (DSO 80 days, DIO 100 days) constrains potential FCF generation by estimated 50-100B yen annually and warrants near-term monitoring as key operational KPI. The company's ability to simultaneously maintain aggressive CapEx (175.6B yen, 1.72x D&A) and comfortable dividend coverage indicates balance sheet capacity for continued growth investments and potential strategic M&A, though recent large non-controlling interest acquisition (81.8B yen) suggests portfolio consolidation focus rather than major new platform additions in near term.
Capital allocation framework demonstrates balance between growth investment, shareholder returns (39.8% total return ratio), and financial flexibility, with conservative 36.8% equity ratio providing dry powder for opportunistic investments while maintaining investment-grade profile. The 1,228.0B yen intangible asset base (35.1% of assets) warrants ongoing monitoring for impairment risk, particularly if Health Science or Oceania beverages segments face margin pressure, though current performance trends show stabilization and improvement suggesting limited near-term impairment probability.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.